AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32246153
Drug: Spaced formats
RxNorm normalized name: formate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spaced formats of Prolonged Exposure (PE) or Present Centered Therapy
Trial: 32667286
Drug: Selgantolimod 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selgantolimod 0.5 mg
Trial: 32667286
Drug: Selgantolimod 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selgantolimod 1.5 mg
Trial: 32667286
Drug: Selgantolimod 3
RxNorm normalized name: Selgantolimod
DrugBank: Selgantolimod (DB16324)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selgantolimod 3 mg
Trial: 32667286
Drug: Selgantolimod 5
RxNorm normalized name: Selgantolimod
DrugBank: Selgantolimod (DB16324)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selgantolimod 5 mg
Trial: 33275318
Drug: Imeglimin 1000
RxNorm normalized name: Fosaprepitant Dimeglumine
DrugBank: Fosaprepitant (DB06717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imeglimin 1000 mg
Trial: 32275365
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) at governor vessel combined with donepezil hydrochloride (5 mg/day, increased to 10 mg/day after 4 weeks if needed) for 8 weeks.
Trial: 32275365
Drug: Donepezil hydrochloride
RxNorm normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil hydrochloride alone (5 mg/day, increased to 10 mg/day after 4 weeks if needed) for 8 weeks.
Trial: 34580704
Drug: Antibiotics while
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics while waiting for surgery
Trial: 34580704
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics while waiting for surgery
Trial: 35645167
Drug: as-needed budesonide-formoterol
RxNorm normalized name: budesonide / formoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as-needed budesonide-formoterol (BFM) (160/4.5 μg)
Trial: 35645167
Drug: budesonide (BUD)
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: budesonide (BUD) (200 μg) twice daily
Trial: 32079739
Drug: Ultrasound-guided rhomboid
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided rhomboid intercostal block with 30 mL 0.25% bupivacaine
Trial: 33478482
Drug: Curcumin extract
RxNorm normalized name: Curcumin Extract 300 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin extract (Curcugen™) 500 mg once daily for 8 weeks
Trial: 33245858
Drug: Prednisone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (100 mg oral for 5 days, tapering 20 mg every 3 days for a total of 17 days)
Trial: 36114520
Drug: Cognitive Enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Enhancement Therapy
Trial: 32776664
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy (EVT) for AIS
Trial: 32424376
Drug: Method A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Method A (presoaking in 1% sodium dodecyl sulfate followed by ultrasonication with 4 mol/L guanidine hydrochloride)
Trial: 32424376
Drug: Method B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Method B (soaking in distilled water followed by ultrasonication with 4 mol/L guanidine hydrochloride)
Trial: 36127097
Drug: Abdominal CT
RxNorm normalized name: PAD,ABDOMINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdominal CT scanning following thoracic low-dose CT (LDCT) for lung cancer screening
Trial: 32570654
Drug: e-Prescription systems
FDA approved: no
EMA approved: no
PMDA approved: no
Description: e-Prescription systems
Trial: 34467834
Drug: Resveratrol 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol 1000 mg daily for 3 months
Trial: 38879571
Drug: Placebo daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for 12 weeks
Trial: 35857241
Drug: Synbiotics (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotics (1 g containing both pre- and probiotics administered twice a day for 14 days)
Trial: 32619715
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) using methylene blue mediated gallium aluminum arsenide laser at 635 nm, 6.5 J/cm2 for 10 seconds at 10 points, applied immediately after first wire and at days 3, 7, 14 of the first month, repeated for additional 2 months.
Trial: 36126327
Drug: STRT+Leu (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STRT+Leu (16 g of protein containing ∼3 g of leucine)
Trial: 33921737
Drug: Fitness training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fitness training protocol consisting of three weekly sessions lasting 90 min
Trial: 32413530
Drug: Beetroot-containing placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot-containing placebo capsules
Trial: 33990958
Drug: Mean arterial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean arterial pressure (MAP) of 60 mm Hg using norepinephrine (NE) infusion
Trial: 33990958
Drug: Mean arterial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean arterial pressure (MAP) of 90 mm Hg using norepinephrine (NE) infusion
Trial: 33813359
Drug: levodopa +
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: levodopa + donepezil (5 mg)
Trial: 36548296
Drug: MAP goal
RxNorm normalized name: OCTINOXATE 7.5 g in 100 g / OXYBENZONE 6 g in 100 g / PADIMATE O 8 g in 100 g TOPICAL LIPSTICK [Goofy Sun Smacker SPF 24 Berry Goal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAP goal of 65 to 85 mmHg (L group)
Trial: 35063002
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine collaborative model (TCMCM) combined with usual adjuvant chemotherapy
Trial: 35063002
Drug: Usual adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual adjuvant chemotherapy
Trial: 36078940
Drug: Ultrasound (US)
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound (US) therapy
Trial: 36006698
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (treatment‐as‐usual)
Trial: 34062937
Drug: Oat β-Glucan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat β-Glucan (1 g OBG, n = 104)
Trial: 34062937
Drug: Oat β-Glucan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat β-Glucan (1 g OBG)
Trial: 35560850
Drug: All dietary
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All dietary treatments (10%, 15%, 20%, 25%, 30% kcal carbohydrate)
Trial: 34180414
Drug: PLIÉ intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PLIÉ intervention (twice weekly classes for 12 weeks)
Trial: 35733098
Drug: Conventional speech
RxNorm normalized name: TRACH TUBE,SPEECH SZ 10 BLOM #313-30-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional speech therapy + functional electrotherapy
Trial: 37282797
Drug: Conventional speech
RxNorm normalized name: TRACH TUBE,SPEECH SZ 10 BLOM #313-30-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional speech therapy
Trial: 36341216
Drug: 25, 75,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25, 75, 150, 300, 450, or 600 mg tafolecimab subcutaneously, 75 or 450 mg intravenously
Trial: 36341216
Drug: 75 or
RxNorm normalized name: Stalevo 75 Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 or 140 mg tafolecimab every 2 weeks, 300 or 420 mg every 4 weeks, or 450 or 600 mg every 6 weeks subcutaneously
Trial: 36341216
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of tafolecimab
Trial: 33039478
Drug: Allergen-specific immunotherapy
RxNorm normalized name: Pacific halibut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergen-specific immunotherapy (AIT) with allergoids to birch and/or grass
Trial: 32381080
Drug: Observation without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Observation without treatment
Trial: 33682648
Drug: Continuation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation with sertraline (50 mg/day)
Trial: 33682648
Drug: Continuation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation with sertraline (100 mg/day)
Trial: 33682648
Drug: Optimized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized treatment (individualized treatment rule)
Trial: 33682648
Drug: Combining mirtazapine
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combining mirtazapine with sertraline
Trial: 36539949
Drug: Standard pharmaceutical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pharmaceutical care (Control)
Trial: 34998427
Drug: Fluralaner (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluralaner (oral administration at the approved dose on day 0)
Trial: 33956987
Drug: VPM-DBS in
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: VPM-DBS in combination with lateral CM stimulation
Trial: 34289755
Drug: Oral semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral semaglutide 14 mg at steady-state with levothyroxine (600 μg single-dose)
Trial: 34289755
Drug: SNAC 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SNAC 300 mg with levothyroxine (600 μg single-dose)
Trial: 34289755
Drug: Oral semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral semaglutide 14 mg at steady-state with five placebo tablets
Trial: 34289755
Drug: Oral semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral semaglutide 14 mg at steady-state alone
Trial: 32723352
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate mucoadhesive tablet
Trial: 37650236
Drug: Bamlanivimab 700
RxNorm normalized name: bamlanivimab 700 MG in 20 mL Injection (EUA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bamlanivimab 700 mg
Trial: 33475701
Drug: Bamlanivimab 2800
RxNorm normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bamlanivimab 2800 mg
Trial: 34981077
Drug: Bamlanivimab 7000
RxNorm normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bamlanivimab 7000 mg
Trial: 33475701
Drug: Bamlanivimab and
RxNorm normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bamlanivimab and Etesevimab (2800 mg each)
Trial: 33836708
Drug: Individually targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individually targeted human milk fortification with protein and fat modulars based on daily point‐of‐care milk analysis.
Trial: 35380713
Drug: Cetuximab 500
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab 500 mg/m2, bevacizumab 5 mg/kg, and irinotecan 180 mg/m2 (CBI)
Trial: 32772304
Drug: Pharmacists reviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacists reviewing medication orders
Trial: 32772304
Drug: Pharmacists monitoring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacists monitoring patients' response to therapy and adverse drug effects
Trial: 32772304
Drug: Collaboration with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaboration with pharmacists in developing treatment plans
Trial: 34825307
Drug: Aromatase inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitors (5 years treatment)
Trial: 34798826
Drug: Pharmacist-led, deprescribing-focused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led, deprescribing-focused medication review, followed by an individualised treatment modification plan.
Trial: 35974369
Drug: Exp I:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exp I: active and passive activity training (APAT) + NMES treatment on the gastrocnemius and tibialis anterior muscle
Trial: 35974369
Drug: Exp II:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exp II: APAT + NMES treatment on gastrocnemius alone
Trial: 32460565
Drug: Calendula ointment
RxNorm normalized name: CALENDULA
DrugBank: Calendula officinalis whole (DB14315)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calendula ointment
Trial: 32698121
Drug: Higher protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher protein diet (2.50 g·kg‐1·day‐1)
Trial: 32698121
Drug: Moderate protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate protein diet (1.25 g·kg‐1·day‐1)
Trial: 38049713
Drug: Conventional fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional fluid therapy
Trial: 33075806
Drug: Dapagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (10 mg) added to verinurad (9 mg) and febuxostat (80 mg)
Trial: 33075806
Drug: Placebo added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo added to verinurad (9 mg) and febuxostat (80 mg)
Trial: 32063089
Drug: Lipid-based nutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutrient supplement (LNS) provided to women during gestation and the first 6 months postpartum and to their infants from age 6 to 18 months.
Trial: 39221611
Drug: Monthly fremanezumab
RxNorm normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Monthly fremanezumab
Trial: 32246762
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone (400 mg pessary) once daily until 37 weeks
Trial: 33599345
Drug: Crocin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crocin (15 mg)
Trial: 33148013
Drug: Edoxaban 60
RxNorm normalized name: edoxaban 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 60 mg (30 mg dose-reduced)
Trial: 33992536
Drug: Intravenous autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous autologous bone marrow-derived mesenchymal stromal cells (BMMSCs) at a dosage of 2 million cells per kilogram of body weight
Trial: 34433601
Drug: Multidisciplinary group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary group programme (Energetic) consisting of a 4 months intervention with weekly meetings covering four modules: aerobic exercise training, education about aerobic exercise, self-management training, and implementation and relapse prevention.
Trial: 34433601
Drug: Suggestions for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suggestions for programme improvement include a combination of face to face and e-health, enhancement of therapists' skills, and inclusion of more booster sessions.
Trial: 35242206
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with rehabilitation therapy
Trial: 33110649
Drug: Topical salicylic
RxNorm normalized name: salicylic acid Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical salicylic acid (SA)
Trial: 36347387
Drug: MSC therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSC therapy (infused at weeks 6 and 7 after transplantation, tacrolimus withdrawn at week 8)
Trial: 35289144
Drug: Conventional-dose CT
RxNorm normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose CT
Trial: 39706874
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus rosiglitazone
Trial: 32820132
Drug: Combined strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined strength and power training (twice a week for 8 weeks)
Trial: 32324130
Drug: NAPSO 220
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAPSO 220 mg
Trial: 32324130
Drug: NAPSO 440
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAPSO 440 mg
Trial: 32324130
Drug: NAPSO 550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAPSO 550 mg
Trial: 32324130
Drug: NAP 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAP 500 mg
Trial: 32324130
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of NAPSO
Trial: 32324130
Drug: Lower doses
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower doses of NAPSO (220 mg, 440 mg)
Trial: 34358343
Drug: Dupilumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab (300 mg) every 2 weeks for 16 weeks
Trial: 32078391
Drug: Pembrolizumab 2
RxNorm normalized name: pembrolizumab 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 2 mg/kg or 10 mg/kg every 3 weeks (up to 35 cycles/2 years)
Trial: 32078391
Drug: Pembrolizumab (second-course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (second-course treatment)
Trial: 32078391
Drug: Pembrolizumab (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (after completing treatment)
Trial: 36598543
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg CBD
Trial: 35583161
Drug: Prowel® (synbiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prowel® (synbiotic drug)
Trial: 34751654
Drug: Printed brochure
RxNorm normalized name: norgestimate
DrugBank: Norgestimate (DB00957)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Printed brochure on nutrition guidelines in addition to usual care for HIV treatment
Trial: 32859145
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 mg/kg dextrose)
Trial: 32459016
Drug: Topical 6%
RxNorm normalized name: menthol topical 6% topical spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 6% gabapentin
Trial: 32459016
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (plain permeation cream)
Trial: 33140403
Drug: MDZ‐NS 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDZ‐NS 5 mg
Trial: 35179756
Drug: Pharmacological Treatment
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological Treatment (PT)
Trial: 35314634
Drug: Belinostat (500-750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belinostat (500-750 mg/m2 1×/day × 5 days every three weeks)
Trial: 35314634
Drug: Control (standard-of-care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard-of-care therapy including temozolomide and radiation therapy)
Trial: 34715827
Drug: Antifungal therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antifungal therapy after surgery
Trial: 34715827
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no antifungal therapy)
Trial: 33813637
Drug: Antifungal therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antifungal therapy
Trial: 34004271
Drug: Synthetic antibiotic
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic antibiotic (ATB)
Trial: 32447657
Drug: Anti-PD-1/PD-L1 monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1/PD-L1 monoclonal antibodies
Trial: 32447657
Drug: Combination immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination immunotherapy
Trial: 32693660
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) along with pharmacotherapy (PT)
Trial: 32693660
Drug: Pharmacotherapy (PT)
RxNorm normalized name: PT-2385
DrugBank: PT-2385 (DB16055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy (PT) only
Trial: 32434001
Drug: Prepregnancy platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prepregnancy platelet factor 4 (third tertile vs first tertile) in aspirin group
Trial: 32860399
Drug: 4000 mg
RxNorm normalized name: talc 4000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4000 mg CLA per day
Trial: 32860399
Drug: 2000 IU
RxNorm normalized name: D 2000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 IU vitamin D-3 and 4000 mg CLA per day
Trial: 35593607
Drug: Nimesulide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide (100 mg) + Thiocolchicoside (8 mg)